# Quentin Lloyd-Harris > Quentin Lloyd-Harris is a Series B investor at Abingworth backing Biotechnology and Health Care. See 9 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Abingworth](https://shizune.co/investors/profile/abingworth-management) - Location: London, United Kingdom - Total investments: 9 - Last investment: Nov 2017 - Lead investor: 44% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/genghis-lloyd-harris-91a63639 Quentin Lloyd-Harris is a Series B investor at Abingworth in London focused on Biotechnology and Health Care. Genghis Lloyd-Harris - Partner @ Abingworth ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 5 | 56% | | Health Care | 4 | 44% | | Therapeutics | 3 | 33% | | Medical | 2 | 22% | | Genetics | 2 | 22% | 6 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series B | 5 | 56% | | Series A | 2 | 22% | | Series C | 1 | 11% | | Funding Round | 1 | 11% | ### Country | Country | Investments | Share | | --- | --- | --- | | Switzerland | 2 | 22% | | France | 1 | 11% | | Sweden | 1 | 11% | | United Kingdom | 1 | 11% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Nouscom | Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy.The NousCom team is lead by experiencedenterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies. | $44.6M | Series B | Nov 06, 2017 | | | GenSight Biologics | GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $36M | Series B | Jul 23, 2015 | | | Wilson Therapeutics | Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a new treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study inWilson Disease patients. | $40M | Series B | Apr 16, 2014 | | | GenSight Biologics | GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $35.1M | Series A | Apr 08, 2013 | | | Syntaxin | Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specificbiotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications. | $29M | Series C | Nov 11, 2010 | | | Synosia Therapeutics | Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend theirreach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease. | $29M | Series B | Jan 01, 2009 | | | Syntaxin | Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specificbiotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications. | $32M | Series B | Oct 31, 2007 | | | Synosia Therapeutics | Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend theirreach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease. | $32.5M | | Jan 05, 2007 | | | Syntaxin | Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specificbiotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications. | $10.4M | Series A | Nov 14, 2005 | | 9 of 9 investments shown. ## Co-investors - [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 3 deals together - [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 2 deals together - [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 2 deals together - [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) — VC Fund, 2 deals together - [LSP BioVentures](https://shizune.co/investors/profile/lsp-bioventures) — VC Fund, 2 deals together - [Fidelity](https://shizune.co/investors/profile/fidelity-management-and-research-company) — VC Fund, 1 deal together ## About Abingworth VC Fund · London, United Kingdom Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciencessectors.Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions. 5 contacts available at Abingworth. | Name | Title | Profile | | --- | --- | --- | | Brian Gallagher | Partner | https://shizune.co/investors/profile/brian-gallagher | | John Shields | Advisor, Science and Technology | https://shizune.co/investors/profile/john-shields | | Quentin Lloyd-Harris | Partner | https://shizune.co/investors/profile/genghis-lloyd-harris | | Alex Asquith | General Counsel and Chief Financial Officer | https://shizune.co/investors/profile/alex-asquith | | Andrew Sinclair | Partner & Portfolio Manager | https://shizune.co/investors/profile/andrew-sinclair | ## Similar investors ### Similar stage - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund - [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund ## FAQ ### What does Quentin Lloyd-Harris invest in? Quentin Lloyd-Harris invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 9 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Quentin Lloyd-Harris last invest? The most recent investment recorded for Quentin Lloyd-Harris closed in Nov 2017. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co